Takeda's TAK-921 improves survival in Phase 3 advanced gastric cancer trial

By Public Technologies
  • Takeda’s arcotatug tavatecan met survival endpoints in Phase 3 G-HOPE-001 in previously treated, advanced CLDN18.2-positive gastric or gastroesophageal junction cancer.
  • Median overall survival reached 10.2 months versus 6.9 months with physician-selected treatment at the September 3, 2026, cutoff (P<0.0001).
  • Median progression-free survival was 7.1 months versus 3.1 months with physician-selected treatment in the second interim analysis.
  • Grade 3 or higher treatment-related adverse events occurred in 47.4% versus 55.9%; one treatment-related death occurred with arcotatug tavatecan.
  • Results will support a planned Japanese regulatory filing; global Phase 3 trials in gastric and pancreatic cancer are planned.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261021967745) on October 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.